Just spoke to MBP suggesting their quarterly report was kind of overdue.
They advised they have opted to hold fire until they release the results of the ACV1 Neuropathic Pain Phase 2 study.
And, as the study is over and results are being compiled keep an eye on the price to give an indication of which way the insiders are calling it!
Did I say that, shame on me ASIC. Losers!